Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: UK Supplying Bivalent Spikevax Via Special Mechanism, Next-Generation BA.4/BA.5 Vaccines Filed In EU

Executive Summary

The European Medicines Agency could make an EU approval recommendation on two bivalent Omicron BA.1-targeting vaccines on 1 September. 

You may also be interested in...



EU OKs Bivalent COVID-19 Vaccines From Pfizer/BioNTech & Moderna

The European Commission will shortly issue marketing authorizations for bivalent versions of Comirnaty and Spikevax targeting the Omicron BA.1 subvariant, after the European Medicines Agency recommended their approval for EU-wide use. Bivalent Spikevax has also been provisionally approved in Australia.

Overhyped? White House COVID Coordinator's Claims About New Boosters Go Beyond Data

Ashish Jha made promises about the upcoming bivalent COVID-19 boosters that neither he nor the companies are likely going to be able to keep when the rollout begins. 

UK First To Approve Moderna’s Bivalent COVID-19 Vaccine

The mRNA-1273.214 vaccine will add to the UK’s armory for protecting people against coronavirus over the coming winter season.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel